Hale Animal Health, a New Zealand-based veterinary pharmaceutical company, has launched what researchers describe as the world's first regulated clinical trial testing a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for treating osteoarthritis in dogs. The study is enrolling more than 100 canines across multiple regions including Waikato, Bay of Plenty, and Christchurch.
Novel Cannabinoid Formulation Targets Common Veterinary Condition
The experimental treatment consists of a liquid formulation containing both THC and CBD, designed to manage pain associated with osteoarthritis without the adverse effects commonly seen with standard anti-inflammatory medications. According to Hale CEO Leila de Koster, osteoarthritis represents one of the most common conditions in veterinary care, making it a significant target for therapeutic intervention.
"Current treatments can be effective but often come with side effects. Our goal is to offer a safe, science-backed alternative that manages pain just as well, without the trade-offs," de Koster explained.
The treatment protocol involves daily administration of the liquid product mixed with the dog's food, with doses measured using a syringe and calculated based on the animal's body weight. Pet owners participating in the trial receive pre-measured bottles of the liquid formulation.
Six-Week Study Design and Patient Benefits
Dogs accepted into the six-week clinical trial receive comprehensive veterinary care at no cost to owners, including full physical examinations, radiographs (X-rays), and blood screening. The study targets dogs of all breeds, both male and female, who have either a confirmed diagnosis of osteoarthritis or are suspected of showing signs of the condition.
De Koster noted that the primary differentiator of this cannabinoid-based approach lies in its side effect profile compared to current pain medications. While existing non-steroidal anti-inflammatory drugs can effectively manage pain, they frequently cause digestive health upset and liver and kidney problems. The new cannabinoid formulation aims to provide equivalent pain relief without these complications.
Regulatory Pathway and Commercial Plans
The clinical trial data will form a crucial component of the regulatory submission package to New Zealand's Agricultural Compounds and Veterinary Medicines (ACVM). This regulatory body will evaluate both efficacy and safety data before potentially granting registration as a veterinary medicine.
Hale's development strategy focuses initially on securing regulatory approval in New Zealand and Australia, with plans already underway for subsequent FDA registration in the United States. The company successfully completed a $2.5 million funding round in 2024 and plans to open another investment round later this year.
Growing Interest in Cannabinoid Veterinary Applications
De Koster reported significant interest from pet owners, stating she regularly receives emails from people inquiring about clinical trial participation opportunities. The veterinary community has also shown enthusiasm for the research, with no reported backlash against the trial.
The Ministry of Health New Zealand recognizes cannabidiol (CBD) as a cannabis-derived substance with therapeutic value and minimal psychoactive properties, providing regulatory context for the study's cannabinoid components.
Dog owners interested in participating in the clinical trial can contact Hale Animal Health at enquiries@haleanimal.co.nz. The main consideration for participation is that dogs currently receiving other pain medications would need to temporarily discontinue those treatments during the trial period.
